UBS analyst Kevin Caliendo raised the firm’s price target on Alignment Healthcare (ALHC) to $17 from $16 and keeps a Neutral rating on the shares. Alignment Healthcare posted a “strong” Q1, with beats across the board, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare Reports Strong Q1 2025 Results
- Alignment Healthcare’s Strong Q1 2025 Performance and Positive Outlook Justify Buy Rating
- Alignment Healthcare sees Q2 revenue $950M-$965M, consensus $945.89M
- Alignment Healthcare raises FY25 revenue view to $3.77B-$3.82B from $3.72B-$3.78
- Alignment Healthcare CFO Thomas Freeman to step down, Jim Head to succeed